HER3 mRNA as a predictive biomarker in anticancer therapy

Bibliography

• Grunwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 2002;26:109-64
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55
   PubMed Web of Science ®Google Scholar
• Tzahar E, Waterman H, Chen X, A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87
   PubMed Web of Science ®Google Scholar
• Junttila TT, Akita RW, Parsons K, Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-40
   PubMed Web of Science ®Google Scholar
• Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993;4:19-26
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004;55:433-57
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting HER2 and discovering HER3. Nat Rev Cancer 2009;9:463-75
   PubMed Web of Science ®Google Scholar
• Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-7
   PubMed Web of Science ®Google Scholar
• Lee-Hoeflich ST, Crocker L, Yao E, A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-87
   PubMed Web of Science ®Google Scholar
• Sergina NV, Rausch M, Wang D, Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;234:177-82
   Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12
   PubMed Web of Science ®Google Scholar
• Carden CP, Banerji U, Kaye SB, From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther 2009;85:131-3
   PubMed Web of Science ®Google Scholar
• Goulart BH, Clark JW, Pien HH, Trends in the use and role of biomarkers in Phase I oncology trials. Clin Cancer Res 2007;13:6719-26
   PubMed Web of Science ®Google Scholar
• Bonavida B, Huerta-Yepez S, Goodglick L, Can we develop biomarkers that predict response of cancer patients to immunotherapy? Biomarkers 2005;10(Suppl 1):S69-76
   PubMedGoogle Scholar
• Lee CM, Shrieve DC, Zempolich KA, Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005;99:415-21
   PubMed Web of Science ®Google Scholar
• Labuhn M, Vuaroqueaux V, Fina F, Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers 2006;21:30-9
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chinratanalab W, Ritter CA, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41
   PubMed Web of Science ®Google Scholar
• Molina MA, Codony-Servat J, Albanell J, Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007;25(18S): abstract 512
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
   PubMed Web of Science ®Google Scholar
• Mass RD, Press MF, Anderson S, Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-6
   PubMedGoogle Scholar
• Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007;96:213-68
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28
   PubMed Web of Science ®Google Scholar
• Baselga J. A review of EGFR targeted therapy. Clin Adv Hematol Oncol 2003;1:218-19
   PubMedGoogle Scholar
• Hubbard SR. EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 2005;7:287-8
   PubMed Web of Science ®Google Scholar
• Friess T, Scheuer W, Hasmann M. Superior anti-tumour activity after combination treatment with pertuzumab and trastuzumab against NSCLC and breast cancer xenograft tumors. Ann Oncol 2006;17(Suppl 9): abstract 96PD
   Google Scholar
• Baselga J, Gelmon KA, Verma S, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that had progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
   PubMed Web of Science ®Google Scholar
• Cortes J, Baselga J, Petrella T, Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2-positive breast cancer. J Clin Oncol 2009;27(15S): abstract 1022
   Google Scholar
• Makhija S, Amler LC, Glenn D, Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2009;28:1215-23
   PubMed Web of Science ®Google Scholar
• Gordon MS, Matei D, Aghajanian C, Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-32
   PubMed Web of Science ®Google Scholar
• Vermeij J, Teugels E, Bourgain C, Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008;8:3
   PubMed Web of Science ®Google Scholar
• Bookman MA, Darcy KM, Clarke-Pearson D, Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003;21:283-90
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Guastalla JP, Couturier J. HER2 overexpression and amplification in advanced ovarian cancer (OC): preliminary results from a large GINECO study. J Clin Oncol 2005;23(16S): abstract 5059
   Google Scholar
• Kaye SB, Poole CJ, Bidzinski M, A randomised Phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. J Clin Oncol 2008;26(18S): abstract 5520
   Google Scholar
• Yao E, Zhou W, Lee-Hoeflich ST, Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009;15:4147-56
   PubMed Web of Science ®Google Scholar
• Nagumo Y, Faratian D, Mullen P, Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res 2009;7:1563-71
   PubMed Web of Science ®Google Scholar
• Tanner B, Hasenclever D, Stern K, ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317-23
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45
   PubMed Web of Science ®Google Scholar
• Krop IE, Burris HA, Rugo H, Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1). J Clin Oncol 2009;27(15S): abstract 1003
   Google Scholar
• Carlson RW, Anderson BO, Burstein HJ, National Comprehensive Cancer Network. Clinical practice guidelines in Oncology™: breast cancer. J Natl Compr Canc Netw 2005;3:238-89
   PubMedGoogle Scholar